Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.

Next Previous
Search
Trial Profile

This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fampridine (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms MILESTONE
  • Sponsors Acorda Therapeutics

    • Most Recent Events

    • 22 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 21 Nov 2016 Primary endpoint (Proportion of subjects who show at least a 20% improvement on the Two Minute Walk Test (2MinWT) at week 12) has not been met, as per an Acordia Therapeutics media release.
    • 21 Nov 2016 Results published in an Acorda Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top